Regenerative and Frontier

Clinic-administered and frontier therapies: therapeutic plasma exchange, hyperbaric oxygen, photobiomodulation, stem cells, exosomes, peptides, gene therapy tourism, IV NAD+. This is where the gap between mechanism and human outcomes matters most.

Start with Therapeutic Plasma Exchange and Plasma Dilution for the section’s core rule: a procedure can be real, technical, and biologically plausible while still lacking clinical longevity-outcome proof. Then read Hyperbaric Oxygen Therapy (HBOT) for the oxygen-exposure version of the same problem: a legitimate clinical device protocol with small human RCT signals, a large wellness-market halo, and no proved healthy-lifespan endpoint. Photobiomodulation (Red and Near-Infrared Light) brings that discipline to the consumer-device edge, where wavelength and dose details matter more than the generic “red light” label. Stem Cell Therapy (Allogeneic MSC, Autologous SVF) and Exosomes extend the same standard to cellular and cell-derived products, where selected disease-specific approvals coexist with systemic packages that operate on case-series-tier evidence and a shifting regulatory map. Peptide Therapeutics applies the same discipline to molecule-specific clinic protocols, unstable compounding status, research-use markets, and the gap between mechanistic repair stories and human outcome evidence. Gene Therapy Tourism and Intravenous NAD+ and Oral NAD+ Precursors mark the far edge of the section: high-cost interventions where mechanism, access, and human outcome evidence have to be separated before anyone can judge the claim.

Read straight through, or land on a specific entry and follow its outgoing links into adjacent interventions, diagnostics, and failure modes.